Buchang Pharma Subsidiary's BC008-1A Injection New Indication Trial Application Accepted by NMPA
Buchang Pharmaceutical's controlling subsidiary, Sichuan Luzhou Buchang Biopharmaceutical Co. , Ltd. , has received acceptance from the National Medical Products Administration (NMPA) for its clinical trial application for a new indication of BC008-1A injection. The drug is a recombinant anti-PD-1/TIGIT humanized bispecific antibody injection, and the proposed new indication is its use in combination with bevacizumab for the treatment of adult recurrent CNS WHO grade 4 glioma. As of July 31, 2026, the project's research and development investment amounted to approximately RMB 115 million. Currently, no bispecific antibody drug targeting the same pathway has been approved for marketing domestically or internationally.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Biotechnology, with intensity 30/100 and 60% confidence over a medium term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.